Significance of novel HBV expression vectors in selecting antiviral drugs in clinical therapy.
- Author:
Yin-ping LU
1
;
Ji-hua DONG
;
Zhao LIU
;
Shi-he GUAN
;
Meng-ji LU
;
Dong-liang YANG
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Antiviral Agents; pharmacology; Drug Evaluation, Preclinical; Drug Resistance, Viral; Female; Hepatitis B; virology; Hepatitis B virus; drug effects; genetics; isolation & purification; Humans; Male; Middle Aged; Virosomes; Young Adult
- From: Chinese Journal of Hepatology 2007;15(1):8-12
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo establish a new method for rapidly selecting anti-hepatitis B virus drugs in clinical therapy.
METHODSThe full-length hepatitis B virus (HBV) genomes from 8 patients with chronic hepatitis B (CHB) were generated by polymerase chain reaction (PCR). All patients were resistant to lamivudine therapy. Their HBV DNA fragments were inserted into Sap I site of pHY106 eukaryotic expression vector separately. The recombinant plasmids containing 1.1 copies of HBV genome were transfected into Huh7 cell line; the levels of HBsAg, HBeAg and HBV DNA in supernatants of Huh7 cells were measured by ELISA and real-time quantitative PCR, and intracellular HBV replicative intermediates were detected by Southern blot. Antiviral effects of lamivudine and adefovir were evaluated in this vitro system.
RESULTSThe 8 recombinant plasmids containing a full-length genome of clinical HBV isolates could replicate and be expressed in Huh 7 cells. There were 6 isolates with polymerase YVDD mutations and 2 isolates with polymerase YIDD mutations. Adefovir, but not lamivudine, inhibited the HBV replication and gene expression in vitro. Furthermore, adefovir inhibited HBV replication in these CHB patients.
CONCLUSIONThe method described here enables a rapid selection of anti-HBV drugs in clinical therapy and is very useful in antiviral therapy for CHB patients.